Bull case
Odyssey Therapeutics is attractive because OD-001 has already shown differentiated Phase 2a evidence in ulcerative colitis, with a 27% clinical remission rate versus roughly 10% historic placebo, a −2.6 modified Mayo score improvement, and a clean safety profile that supports both monotherapy and combination use. Its thesis is strengthened by a broad innate-immunity pipeline and modality-agnostic discovery engine, including OD-002, OD-003, and earlier-stage IRAK4, TNFR2, and TSLP/IL-33 programs, which diversify risk and create multiple shots on goal across large autoimmune and inflammatory markets. Financially, the company ended March with $175.7M in cash and added about $315M from the IPO and concurrent financing, while management’s 2026 operating expense estimate of $213.3M suggests it is still loss-making but funded to advance upcoming 2H26 and 2H27 catalysts.